Please login to the form below

Not currently logged in
Email:
Password:

Pearl Therapeutics

This page shows the latest Pearl Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: AstraZeneca's new San Fran home, Keytruda triumphs again, Novo branches out

Daily Brief: AstraZeneca's new San Fran home, Keytruda triumphs again, Novo branches out

The state-of-the-art labs bring together researchers from four parts of the AZ family – the 2013-acquired Pearl Therapeutics, 2015- acquired Acerta Pharma, plus MedImmune, and AstraZeneca’s TIDE

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

  • Pharma deals during June 2013 Pharma deals during June 2013

    Respiratory acquisitions. Continuing its run of deal activities, AstraZeneca (AZ) built on its respiratory interests with the acquisition of Pearl Therapeutics at a headline value of $1.15bn. ... AZ paid an initial $560m for Pearl's shares and a deferred

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Kala names Howard Rosen as chairman Kala names Howard Rosen as chairman

    He is former CEO of Pearl Therapeutics and VP at Gilead. ... His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to $1.15bn, as well as

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics